Diagnostics and treatment challenges of Ph-like acute lymphoblastic leukemia: a description of 3 clinical cases
- Authors: ZARUBINA KI1, PAROVICHNIKOVA EN1, BASKHAEVA GA1, KRASILNIKOVA AE1, GAVRILINA OA1, BIDERMAN BV1, SUDARIKOV AB1, BONDARENKO SN2, DAVYDOVA YO1, GALTSEVA IV1, SOKOLOV AN1, TROITSKAYA VV1, SAVCHENKO VG1
-
Affiliations:
- National Research Center for Hematology
- Pavlov First Saint Petersburg State Medical University
- Issue: Vol 90, No 7 (2018)
- Pages: 110-117
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32813
- DOI: https://doi.org/10.26442/terarkh2018907110-117
- ID: 32813
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
K I ZARUBINA
National Research Center for Hematology
Email: ksenijazarubina@mail.com
врач-гематолог, аспирант отд-ния интенсивной терапии гемобластозов и депрессий кроветворения со стационаром дневного пребывания; http://orcid.org/0000-0003-2947-6398 Moscow, Russia
E N PAROVICHNIKOVA
National Research Center for Hematologyд.м.н., проф., руководитель отдела химиотерапии гемобластозов, депрессий кроветворения и ТКМ ФГБУ «НМИЦ гематологии» МЗ РФ, http://orcid.org/0000-0001-6177-3566 Moscow, Russia
G A BASKHAEVA
National Research Center for Hematologyаспирант, врач-гематолог отд-ния интенсивной высокодозной химиотерапии гемобластозов и депрессий кроветворения с круглосуточным и дневным стационарами ФГБУ «НМИЦ гематологии» МЗ РФ, https://orcid.org/0000-0003-2763-5391 Moscow, Russia
A E KRASILNIKOVA
National Research Center for Hematologyклинический ординатор отд-ния интенсивной высокодозной химиотерапии гемобластозов и депрессий кроветворения с круглосуточным и дневным стационарами ФГБУ «НМИЦ гематологии» МЗ РФ, https://orcid.org/0000-0001-6230-6513 Moscow, Russia
O A GAVRILINA
National Research Center for Hematologyк.м.н., врач-гематолог, с.н.с. отд-ния интенсивной высокодозной химиотерапии гемобластозов и депрессий кроветворения с круглосуточным и дневным стационарами ФГБУ «НМИЦ гематологии» МЗ РФ, http://orcid.org/0000-0002-9969-8482 Moscow, Russia
B V BIDERMAN
National Research Center for Hematologyк.б.н., с.н.с. научно-клинической лаборатории молекулярной гематологии ФГБУ «НМИЦ гематологии» МЗ РФ, http://orcid.org/0000-0002-6253-3334 Moscow, Russia
A B SUDARIKOV
National Research Center for Hematologyд.б.н., зав. научно-клинической лаборатории молекулярной гематологии ФГБУ «НМИЦ гематологии» МЗ РФ, https://orcid.org/0000-0001-9463-9187 Moscow, Russia
S N BONDARENKO
Pavlov First Saint Petersburg State Medical Universityк.м.н. доцент каф. гематологии, трансфузиологии и трансплантологии ФПО Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова Saint Petersburg, Russia
Y O DAVYDOVA
National Research Center for Hematologyврач КДЛ, лаборатория иммунофенотипирования клеток крови и костного мозга ФГБУ «НМИЦ гематологии» МЗ РФ, https://orcid.org/0000-0001-5932-0285 Moscow, Russia
I V GALTSEVA
National Research Center for Hematologyд.б.н., зав. научно-клинической лаборатории молекулярной гематологии ФГБУ «НМИЦ гематологии» МЗ РФ, https://orcid.org/0000-0001-9463-9187 Moscow, Russia
A N SOKOLOV
National Research Center for Hematologyк.м.н., с.н.с. отд-ния интенсивной высокодозной химиотерапии гемобластозов и депрессий кроветворения с круглосуточным и дневным стационарами ФГБУ «НМИЦ гематологии» МЗ РФ, http://orcid.org/0000-0003-1494-7978 Moscow, Russia
V V TROITSKAYA
National Research Center for Hematologyк.м.н., зав. отд-нием высокодозной химиотерапии гемобластозов и депрессий кроветворения с круглосуточным и дневным стационарами ФГБУ «НМИЦ гематологии» МЗ РФ, http://orcid.org/0000-0002-4827-8947 Moscow, Russia
V G SAVCHENKO
National Research Center for Hematologyпроф., академик РАН, д.м.н., директор ФГБУ «НМИЦ гематологии» МЗ РФ, http://orcid.org/0000-0001-8188-5557 Moscow, Russia
References
- Thomas D, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen J, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating M, Cortes J and Kantarjian H. Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome-Negative Precursor B-Lineage Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 2010; 28(24):3880-3889. https://doi.org/10.1200/ JCO.2009.26.9456
- Moorman A.V. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Reviews. 2012;26(3):123-135. https://doi.org/10.1016/j.blre.2012. 01.001
- Den Boer M.L, van Slegtenhorst M, De Menezes R.X, Cheok M.H, Buijs-Gladdines J.G, Peters S.T, Van Zutven L.J, Beverloo H.B, Van der Spek P.J, Escherich G, Horstmann M.A, Janka-Schaub G.E, Kamps W.A, Evans W.E, Pieters R. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome - wide classification study. The Lancet Oncology. 2009;10(2):125-134. https://doi.org/10. 1016/S1470-2045(08)70339-5
- Mullighan C.G, Su X, Zhang J, Radtke I, Phillips L.A, Miller C.B, Ma J, Liu W, Cheng C, Schulman B.A, Harvey R.C, Chen I.M, Clifford R.J, Carroll W.L, Reaman G, Bowman W.P, Devidas M, Gerhard D.S, Yang W, Relling M.V, Shurtleff S.A, Campana D, Borowitz M.J, Pui C.H, Smith M, Hunger S.P, Willman C.L, Downing J.R; Children's Oncology Group. Deletion of IKZF1and Prognosis in Acute Lymphoblastic Leukemia. New England Journal of Medicine. 2009;360(5):470-480. https://doi.org/10.1056/nejmoa0808253
- Roberts K.G, Li Y, Payne-Turner D, Harvey R.C, Yang Y.L, Pei D, Mc Castlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen S.C, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton R.S, Wen J, Valentine M, Cheng C, Paugh S.W, Devidas M, Chen I.M, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, Winick N.J, Larsen E.C, Carroll W.L, Heerema N.A, Carroll A.J, Grayson G, Tasian S.K, Moore A.S, Keller F, Frei-Jones M, Whitlock J.A, Raetz E.A, White D.L, Hughes T.P, Guidry Auvil J.M, Smith M.A, Marcucci G, Bloomfield C.D, Mrózek K, Kohlschmidt J, Stock W, Kornblau S.M, Konopleva M, Paietta E, Pui C.H, Jeha S, Relling M.V, Evans W.E, Gerhard D.S, Gastier-Foster J.M, Mardis E, Wilson R.K, Loh M.L, Downing J.R, Hunger S.P, Willman C.L, Zhang J, Mullighan C.G. Targetable Kinase-Activating Lesions in Ph - like Acute Lymphoblastic Leukemia. New England Journal of Medicine. 2014;371(11):1005-1015. https://doi.org/10.1056/nejmoa1403088
- Herold T, Baldus C, Gökbuget N. Ph - like Acute Lymphoblastic Leukemia in Older Adults. New England Journal of Medicine. 2014;371(23):2235-2235. https://doi.org/10.1056/nejmc1412123
- Herold T, Schneider S, Metzeler K.H, Neumann M, Hartmann L, Roberts K.G, Konstandin N.P, Greif P.A, Bräundl K, Ksienzyk B, Huk N., Schneider I, Zellmeier E, Jurinovic V, Mansmann U, Hiddemann W, Mullighan C.G, Bohlander S.K, Spiekermann K, Hoelzer D, Brüggemann M, Baldus C.D, Dreyling M, Gökbuget N. Adults with Philadelphia chromosome - like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis. Haematologica. 2016;102(1):130-138. https://doi.org/10.3324/haematol.2015.136366
- Jain N, Roberts K.G, Jabbour E, Patel K, Eterovic A.K, Chen K, Zweidler-Mc Kay P, Lu X, Fawcett G, Wang S.A, Konoplev S, Harvey R.C, Chen I.M, Payne-Turner D, Valentine M, Thomas D, Garcia-Manero G, Ravandi F, Cortes J, Kornblau S, O'Brien S, Pierce S, Jorgensen J, Shaw K.R, Willman C.L, Mullighan C.G, Kantarjian H, Konopleva M. Ph - like acute lymphoblastic leukemia: a high - risk subtype in adults. Blood. 2016;129(5):572-581. https://doi.org/10.1182/blood-2016-07-726588
- Roberts K.G, Gu Z, Payne-Turner D, Mc Castlain K, Harvey R.C, Chen I.M, Pei D, Iacobucci I, Valentine M, Pounds S.B, Shi L, Li Y, Zhang J, Cheng C, Rambaldi A, Tosi M, Spinelli O, Radich J.P, Minden M.D, Rowe J.M, Luger S, Litzow M.R, Tallman M.S, Wiernik P.H, Bhatia R, Aldoss I, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield C.D, Stock W, Kornblau S, Kantarjian H.M, Konopleva M, Paietta E, Willman C.L, Mullighan C.G. Roberts K, Gu Z, Payne-Turner D et al. High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. Journal of Clinical Oncology. 2017;35(4):394-401. https://doi.org/10.1200/jco.2016.69.0073
- Boer J.M, Koenders J.E, van der Holt B, Exalto C, Sanders M.A, Cornelissen J.J, Valk P.J, den Boer M.L, Rijneveld A.W. Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non - response and relapse rates. Haematologica. 2015;100(7):e261-e264. https://doi.org/10.3324/ haematol.2014.117424
- Imamura T, Kiyokawa N, Kato M, Imai C, Okamoto Y, Yano M, Ohki K, Yamashita Y, Kodama Y, Saito A, Mori M, Ishimaru S, Deguchi T, Hashii Y, Shimomura Y, Hori T, Kato K, Goto H, Ogawa C, Koh K, Taki T, Manabe A, Sato A, Kikuta A, Adachi S, Horibe K, Ohara A, Watanabe A, Kawano Y, Ishii E, Shimada H. Characterization of pediatric Philadelphia - negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan. Blood Cancer J. 2016;6(5): e419-e419. https://doi.org/10.1038/bcj.2016.28
- van der Veer A, Waanders E, Pieters R, Willemse M.E, Van Reijmersdal S.V, Russell L.J, Harrison C.J, Evans W.E, van der Velden V.H, Hoogerbrugge P.M, Van Leeuwen F, Escherich G, Horstmann M.A, Mohammadi Khankahdani L, Rizopoulos D, De Groot-Kruseman H.A, Sonneveld E, Kuiper R.P, Den Boer M.L. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood. 2013;122(15):2622-2629. https://doi.org/10.1182/blood-2012-10-462 358
- Loh M.L, Zhang J, Harvey R.C, Roberts K, Payne-Turner D, Kang H, Wu G, Chen X, Becksfort J, Edmonson M, Buetow K.H, Carroll W.L, Chen I.M, Wood B, Borowitz M.J, Devidas M, Gerhard D.S, Bowman P, Larsen E, Winick N, Raetz E, Smith M, Downing J.R, Willman C.L, Mullighan C.G, Hunger S.P. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood. 2012;121(3):485-488. https://doi.org/ 10.1182/blood-2012-04-422691
- Harvey R.C, Mullighan C.G, Chen I.M, Wharton W, Mikhail F.M, Carroll A.J, Kang H, Liu W, Dobbin K.K, Smith M.A, Carroll W.L, Devidas M, Bowman W.P, Camitta B.M, Reaman G.H, Hunger S.P, Downing J.R, Willman C.L. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010;115(26):5312-5321. https://doi.org/10.1182/blood-2009-09-245944
- Boer J.M, Marchante J.R, Evans W.E, Horstmann M.A, Escherich G, Pieters R, Den Boer M.L. CR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures. Haematologica. 2015;100(9):e354-e357. https://doi.org/10.3324/haematol.2015.124941
- Russell L.J, Capasso M, Vater I, Akasaka T, Bernard O.A, Calasanz M.J, Chandrasekaran T, Chapiro E, Gesk S, Griffiths M, Guttery D.S, Haferlach C, Harder L, Heidenreich O, Irving J, Kearney L, Nguyen-Khac F, Machado L, Minto L, Majid A, Moorman A.V, Morrison H, Rand V, Strefford J.C, Schwab C, Tönnies H, Dyer M.J, Siebert R, Harrison C.J. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 2009;114(13):2688-2698. https://doi.org/10.1182/ blood-2009-03-208397
- Mullighan C.G, Collins-Underwood J.R, Phillips L.A, Loudin M.G, Liu W, Zhang J, Ma J, Coustan-Smith E, Harvey R.C, Willman C.L, Mikhail F.M, Meyer J, Carroll A.J, Williams R.T, Cheng J, Heerema N.A, Basso G, Pession A, Pui C.H, Raimondi S.C, Hunger S.P, Downing J.R, Carroll W.L, Rabin K.R. Rearrangement of CRLF2 in B-progenitor - and Down syndrome - associated acute lymphoblastic leukemia. Nat Genet. 2009;41(11):1243-1246. https://doi.org/10.1038/ng.469
- Mullighan C.G, Zhang J, Harvey R.C, Collins-Underwood J.R, Schulman B.A, Phillips L.A, Tasian S.K, Loh M.L, Su X, Liu W, Devidas M, Atlas S.R, Chen I.M, Clifford R.J, Gerhard D.S, Carroll W.L, Reaman G.H, Smith M, Downing J.R, Hunger S.P, Willman C.L. JAK mutations in high - risk childhood acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences. 2009;106(23):9414-9418. https://doi.org 10.1073/pnas.0811761106
- Weston B.W, Hayden M.A, Roberts K.G, Bowyer S, Hsu J, Fedoriw G, Rao K.W, Mullighan C.G. Tyrosine Kinase Inhibitor Therapy Induces Remission in a Patient With Refractory EBF1-PDGFRB-Positive Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 2013;31(25):e413-e416. https://doi.org 10.1200/jco.2012.47.6770
- Lengline E, Beldjord K, Dombret H, Soulier J, Boissel N, Clappier E. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica. 2013;98(11):e146-e148. https://doi.org 10.3324/ haematol.2013.095372
- Roberts K.G, Morin R.D, Zhang J, Hirst M, Zhao Y, Su X, Chen S.C, Payne-Turner D, Churchman M.L, Harvey R.C, Chen X, Kasap C, Yan C, Becksfort J, Finney R.P, Teachey D.T, Maude S.L, Tse K, Moore R, Jones S, Mungall K, Birol I, Edmonson M.N, Hu Y, Buetow K.E, Chen I.M, Carroll W.L, Wei L, Ma J, Kleppe M, Levine R.L, Garcia-Manero G, Larsen E, Shah N.P, Devidas M, Reaman G, Smith M, Paugh S.W, Evans W.E, Grupp S.A, Jeha S, Pui C.H, Gerhard D.S, Downing J.R, Willman C.L, Loh M, Hunger S.P, Marra M.A, Mullighan C.G. Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia. Cancer Cell. 2012;22(2):153-166. https://doi.org 10.1016/j.ccr.2012.06.005
- Maude S.L, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, Ryan T, Hall J, Wood A.C, Tasian S.K, Hunger S.P, Loh M.L, Mullighan C.G, Wood B.L, Hermiston M.L, Grupp S.A, Lock R.B, Teachey D.T. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015;125(11):1759-1767. https://doi.org 10.1182/ blood-2014-06-580480
- Wilhelm S.M, Carter C, Tang L, Wilkie D, Mc Nabola A, Rong H, Chen C, Zhang X, Vincent P, Mc Hugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post L.E, Bollag G, Trail P.A. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. Cancer Res. 2004; 64(19):7099-7109. https://doi.org 10.1158/0008-5472.can-04-1443
- Roberts K, Mullighan C. Genomics in acute lymphoblastic leukaemia: insights and treatment implications. Nature Reviews Clinical Oncology. 2015;12(6):344-357. https://doi.org 10.1038/nrclinonc.2015.38
- Pui C, Roberts K, Yang J, Mullighan C. Philadelphia Chromosome - like Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia. 2017;17(8):464-470. https://doi.org 10.1016/j.clml. 2017.03.299
- Churchman M.L, Evans K, Richmond J, Robbins A, Jones L, Shapiro I.M, Pachter J.A, Weaver D.T, Houghton P.J, Smith M.A, Lock R.B, Mullighan C.G. Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL. JCI Insight. 2016;1(4). https://doi.org 10.1172/jci.insight.86082
- Churchman M.L, Low J, Qu C, Paietta E.M, Kasper L.H, Chang Y, Payne-Turner D, Althoff M.J, Song G, Chen S.C, Ma J, Rusch M, Mc Goldrick D, Edmonson M, Gupta P, Wang Y.D, Caufield W, Freeman B, Li L, Panetta J.C, Baker S, Yang Y.L, Roberts K.G, Mc Castlain K, Iacobucci I, Peters J.L, Centonze V.E, Notta F, Dobson S.M, Zandi S, Dick J.E, Janke L, Peng J, Kodali K, Pagala V, Min J, Mayasundari A, Williams R.T, Willman C.L, Rowe J, Luger S, Dickins R.A, Guy R.K, Chen T, Mullighan C.G. Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. Cancer Cell. 2015;28(3):343-356. https://doi.org 10.1016/j.ccell.2015.07.016
- Kantarjian H, Stein A, Gökbuget N, Fielding A.K, Schuh A.C, Ribera J.M, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz M.A, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst H.A, Brüggemann M, Klapper W, Wood B.L, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp M.S. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. New England Journal of Medicine. 2017;376(9):836-847. https://doi.org 10.1056/nejmoa1609783
- Sokolov A.N, Parovichnikova E.N, Troitskaya V.V, Kuzmina L.A, Galtseva I.V, Kulikov S.M, Bondarenko S.N, Davidova J.O, Kapranov N.M, Lukyanova I.A, Lobanova T.I, Usikova E.I, Zarubina K.I, Savchenko V.G. Blinatumomab + Tyrosine Kinase Inhibitors with No Chemotherapy in BCR-ABL-Positive or IKZF1-Deleted or FLT3-ITD-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia Patients: High Molecular Remission Rate and Toxicity Profile. Blood. 2017;130:3884.
- Sokolov A, Parovichnikova E, Troitskaya V, Galtseva I, Kuzmina L, Davidova J, Kapranov N, Lukyanova I, Lobanova T, Zarubina K, Usikova E, Savchenko V. Targetable blinatumomab + tyrosine kinase inhibitors treatment in relapsed/refractory acute lymphoblastic leukemia patients: clinical effectiveness and peripheral lymphocytes subpopulations kinetics. Haematologica. 2017; 102(s2):354-355.